抗抑郁药安全性监测:基于大数据的SSRI与SNRI严重事件主动信号检测
本研究在丹麦全国医疗数据(1996-2016)中模拟主动监测系统,对969,667例SSRI/SNRI新使用者进行重复年度队列分析,随访最长6个月。共识别31个潜在安全信号组合,其中21个(67.7%)未见于现行产品特征摘要,证明序贯累积分析用于近实时药物警戒的可行性。
要点
- 序贯累积分析可近实时检测抗抑郁药潜在安全信号,最低发生率低至0.9/万患者年。
- 31个潜在安全信号中21个(67.7%)未在现行产品特征摘要中列出,提示需进一步评估。
- 研究覆盖8种暴露药物和51种医学事件,随访最长6个月。
核心结论
- 使用序贯累积分析进行流行病学监测是可行的,可近实时检测SSRI和SNRI起始后的潜在安全信号。
- 识别出的31个潜在安全信号中21个(67.7%)未见于现行产品特征摘要,建议在前瞻性设置中出现时指定进一步评估。
研究设计与样本
- 在丹麦全国医疗数据(1996-2016)中模拟主动监测系统,进行重复年度队列研究。
- 纳入969,667例SSRI或SNRI新使用者,随访最长6个月,总随访461,506人年。
- 使用Cox回归分析调整标准协变量集,通过热图和累积风险比图可视化潜在安全信号。
主要发现
- 检测到潜在安全信号的发生率低至0.9/万患者年。
- 涉及8种暴露药物和51种医学事件,识别出31个与暴露组事件正相关的独特潜在安全信号组合。
- 31个潜在安全信号中21个(67.7%)未出现在现行产品特征摘要中。
关键数值与推荐
- 结局选自欧洲药品管理局指定医学事件列表、产品特征摘要和文献。
- 潜在安全信号定义为暴露组中与感兴趣事件正相关的组合,通过累积风险比图随时间可视化。
临床怎么用
- 临床药学智能体可参考序贯累积分析框架,利用大数据近实时监测抗抑郁药起始后的严重医学事件。
- 对未见于产品特征摘要的潜在安全信号(如本研究中的21个)应保持警惕,必要时进一步评估。
局限性
- 评估罕见事件和少用抗抑郁药需要更大规模人群。
- 研究为历史模拟主动监测,信号需在前瞻性设置中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The current process for generating evidence in pharmacovigilance has several limitations, which often lead to delays in the evaluation of drug-associated risks. OBJECTIVES: In this study, we proposed and tested a near real-time epidemiological surveillance system using sequential, cumulative analyses focusing on the detection and preliminary risk quantification of potential safety signals following initiation of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). METHODS: We emulated an active surveillance system in an historical setting by conducting repeated annual cohort studies using nationwide Danish healthcare data (1996-2016). Outcomes were selected from the European Medicines Agency's Designated Medical Event list, summaries of product characteristics, and the literature. We followed patients for a maximum of 6 months from treatment initiation to the event of interest or censoring. We performed Cox regression analyses adjusted for standard sets of covariates. Potential safety signals were visualized using heat maps and cumulative hazard ratio (HR) plots over time. RESULTS: In the total study population, 969,667 new users were included and followed for 461,506 person-years. We detected potential safety signals with incidence rates as low as 0.9 per 10,000 person-years. Having eight different exposure drugs and 51 medical events, we identified 31 unique combinations of potential safety signals with a positive association to the event of interest in the exposed group. We proposed that these signals were designated for further evaluation once they appeared in a prospective setting. In total, 21 (67.7%) of these were not present in the current summaries of product characteristics. CONCLUSION: The study demonstrated the feasibility of performing epidemiological surveillance using sequential, cumulative analyses. Larger populations are needed to evaluate rare events and infrequently used antidepressants.
引用
- Aakjær M, De Bruin ML, Kulahci M, et al. Surveillance of Antidepressant Safety (SADS): Active Signal Detection of Serious Medical Events Following SSRI and SNRI Initiation Using Big Healthcare Data. Drug Saf. 2021. PMID: 34498210. doi:10.1007/s40264-021-01110-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。